A Shared Care Agreement (SCA) is a local guideline that outlines the responsibilities of the specialist and the GP for the prescribing and monitoring of medicines, once a patient is stable on that medicine.
This letter has recently been circulated to all practices in Lincolnshire regarding the current status of Shared Care Agreements.
Below is a list of approved Shared Care Agreements for Lincolnshire:
National Shared Care Protocols
The following shared care protocols are national protocols developed by RMOC and published on the NHS England website. They have been adopted and adapted for local use and approved by PACEF
|Azathioprine and Mercaptopurine SCA
Local Shared Care Protocols
The following shared care protocols have been produced locally using the national protocol template developed by RMOC. They have been approved by PACEF.
Paediatric Shared Care Protocols
These protocols are only to be used for patients under the care of Lincolnshire based community paediatric services. For those patients under the care of specialist services based outside of Lincolnshire, shared care protocols should be provided by those services. These are not to be used for adult patients.
October 2023 - due to an ongoing national shortage of drugs used for attention deficit hyperactivity disorder, the availability of products has been reviewed and it has been agreed that restrictions on brands of products should be suspended while the supply disruption continues.
The ICS guidance can be found here.
Renal Shared Care Protocols
These protocols are only to be used for those patients under the care of Lincolnshire based renal services. For those patients under the care of specialist services based outside of Lincolnshire, shared care protocols should be provided by those services
|Tacrolimus MR SCA
|Mycophenolic Acid SCA
|Calcium Phosphate Binders SCA
Shared Care Protocols Granted Extensions
The following protocols are currently under review. All these protocols have had their content checked by ULHT/LPFT Pharmacists and have had their review dates extended as listed below, to enable sufficient time to develop these into the new format. This extension for dementia and ketamine was approved at PACEF - 15th March 2023.